Coya Therapeutics, Inc.
NASDAQ:COYABiotechnology
-$0.16 today
- Market cap
- $72.48M
- Beta
- 0.62
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$1.26
Volume 0.15M
Average 0.16M
COYA Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Coya Therapeutics, Inc.NASDAQ: COYA
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $11M rose 57356.2% year over year, ahead of the +111.9% change in trailing-twelve-month financing cash flow. Sequentially, it fell 46.0% from the prior quarter. Over 3 fiscal years it compounded at +29.6% a year.
Context
- Financing cash flow amounted to 256.6% of revenue in FY2025, down 194.4 pp from a year earlier.
- Financing cash flow increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +57356.2% holds above the trailing-twelve-month pace of +111.9%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 20.39M USD
- Year-over-year change
- +27.2%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 20.39M | +27.2% |
| FY2024 | 2024-12-31 | 16.03M | -58.3% |
| FY2023 | 2023-12-31 | 38.43M | +310.6% |
| FY2022 | 2022-12-31 | 9.36M | +2847.6% |
| FY2021 | 2021-12-31 | (340.58K) | — |
Financing Cash Flow vs competitors
How COYA compares with its peers on the latest reported figures
- COYA's LTM Mar 2026 financing cash flow of $31.36M is the 7th largest of the 11 companies compared; the peer median is $41.83M.
- Its year-over-year change of +111.9% is the 6th highest of 10, against a peer median of +1110.6%.
- Financing cash flow amounts to 395.1% of revenue for COYA, versus a peer median of 2305.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $164.18M | +40238.1% | +646.7% | 2305.2% | |
| LTM Mar 2026 | $107.35M | — | +221.5% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Dec 2025 | $94.38M | +72496.9% | +9.1% | 1320.9% |
| LTM Mar 2026 | $70.43M | +7606.1% | +538.8% | 7043.4% | |
| LTM Mar 2026 | $69.59M | +16083.5% | +247.3% | 44.3% | |
| LTM Mar 2026 | $32.12M | -1858.1% | — | — | |
| LTM Mar 2026 | $31.36M | +111.9% | +29.6% | 395.1% | |
| LTM Mar 2026 | $15.14M | -54.2% | — | — | |
| LTM Mar 2026 | $14.08M | +1110.6% | -12.6% | 10506.7% | |
| LTM Mar 2026 | $5.59M | -2029.0% | — | — | |
| LTM Mar 2026 | $0 | -100.0% | -46.9% | — | |
| Peer median (excluding COYA) | $41.83M | +1110.6% | +221.5% | 2305.2% | |
Competitors are the stored peer set for COYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (4.89M) | (12.24M) | (7.99M) | (14.88M) | (21.23M) |
| Depreciation & Amortization | 16.13K | 27.36K | 27.36K | 27.36K | 27.36K |
| Deferred Income Tax | 399.68K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 233.22K | 207.35K | 872.25K | 2.66M | 4.29M |
| Change in Working Capital | 739.17K | 751.84K | (4.64M) | 1.88M | 3.88M |
| Accounts Receivables | 0 | 0 | (7.5M) | 7.5M | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 665.17K | 845.28K | 298.82K | 477.45K | (527.01K) |
| Other Working Capital | 74K | (93.45K) | 2.56M | (6.1M) | 4.41M |
| Other Non-Cash Items | (399.68K) | 4.02M | 543.19K | 25K | 2.29M |
| Operating Cash Flow | (3.9M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
| Capital Expenditures | (136.8K) | 0 | 0 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (525K) | (543.19K) | (25K) | 0 |
| Investing Cash Flow | (136.8K) | (525K) | (543.19K) | (25K) | (1.16M) |
| Debt Repayment | 0 | 10.47M | 0 | 0 | 0 |
| Common Stock Issued | 1.32K | 158 | 38.34M | 14M | 20.35M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (341.9K) | (1.11M) | 89.95K | 2.02M | 0 |
| Financing Cash Flow | (340.58K) | 9.36M | 38.43M | 16.03M | 20.39M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (4.38M) | 1.59M | 26.69M | 5.71M | 8.48M |
| Free Cash Flow | (4.04M) | (7.24M) | (11.19M) | (10.29M) | (10.74M) |
Coya Therapeutics, Inc.
NASDAQ:COYA
Intrinsic Alpha fair value
Locked
Current Price
$3.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.